Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TPI 287

Drug Profile

TPI 287

Alternative Names: ARC-100; NBT 287; TPI-287

Latest Information Update: 28 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tapestry Pharmaceuticals
  • Developer Archer Biosciences; Cortice Biosciences; H. Lee Moffitt Cancer Center and Research Institute; Tapestry Pharmaceuticals; University of California at San Francisco; University of Texas M. D. Anderson Cancer Center; Van Andel Research Institute
  • Class Antidementias; Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Microtubule protein modulators; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Progressive supranuclear palsy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Glioblastoma
  • Phase I/II Malignant melanoma
  • No development reported Alzheimer's disease; Cancer; Corticobasal degeneration; Medulloblastoma; Neuroblastoma; Non-small cell lung cancer; Progressive supranuclear palsy
  • Discontinued Pancreatic cancer; Prostate cancer

Most Recent Events

  • 28 Nov 2023 No recent reports of development identified for phase-I development in Alzheimer's-disease in USA (IV, Infusion)
  • 28 Nov 2023 No recent reports of development identified for phase-I development in Corticobasal-degeneration in USA (IV, Infusion)
  • 28 Nov 2023 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Metastatic disease) in USA (IV, Infusion)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top